Research Article
Glycemic Characteristics and Clinical Outcomes in Patients with COVID-19 Admitted to Referral Shahid Sayad Shirazi Hospital in Gorgan, North of Iran
Table 2
The glycemic profile of COVID-19 patients.
| | Factors | Frequency (%) |
| | History of DM | 168 (40.2) | | Glycemic category based on FBS (mg/dl) during hospitalization regardless of the previous history of DM | | Normal (FBS < 100) | 36 (8.6) | | Pre-DM (100 < FBS < 125) | 32 (7.7) | | DM (FBS < 125) | 350 (83.7) | | Drugs used for DM | | Oral except metformin | 17 (10.2) | | Metformin | 70 (42.2) | | Insulin | 50 (30.1) | | Metformin + oral | 23 (13.9) | | Insulin + oral | 6 (3.6) |
| | Factors | Mean ± SD (range) |
| | FBS during hospitalization (mg/dl) | 195.2 ± 63.6 (73–481) | | Random BS during hospitalization (mg/dl) | 219.9 ± 68.2 (83–500) | | Average insulin dose during hospitalization (unit) | 9.1 ± 5.9 (2–40) |
|
|
DM, diabetes mellitus; FBS, fasting blood sugar; BS, blood sugar.
|
